Vivani

Vivani Medical is a clinical stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. Leveraging its proprietary NanoPortal™ platform, Vivani’s portfolio of tiny, subdermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. Vivani is initially focused on developing a miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-139 (semaglutide). In addition, the company is developing NPM-133, a semaglutide implant for the treatment of type 2 diabetes.